Menu
Oracle buys ClearTrial for clinical trials software

Oracle buys ClearTrial for clinical trials software

The deal builds on Oracle's portfolio of related applications

Oracle said Thursday it has acquired ClearTrial, which offers cloud-based applications that help companies run clinical trials of new drugs. Terms of the deal, which is expected to close in the first half of this year, were not disclosed.

ClearTrial's capabilities will be combined with related assets in Oracle's software portfolio, such as those gained through its 2010 acquisition of Phase Forward. That purchase in turn built on Oracle's 2009 purchase of drug-safety software vendor Relsys.

The cost of conducting clinical trials is on the rise, and ClearTrial's software will give Oracle "leading budgeting, forecasting and analytics capabilities" that can help keep expenses down, Oracle said in a FAQ document on the acquisition.

The company's technology is complementary to Oracle's related products and customers' investments in ClearTrial will be protected, according to the FAQ.

ClearTrial's customers include some of the world's largest biopharmaceutical companies, among them Genentech and Astra-Zeneca, according to its website.

The acquisitions of ClearTrial, Phase Forward and Relsys are part of Oracle's intention to "paint an end-to-end health care vision" spanning everything from drug discovery to areas such as drug manufacturing, distribution and patient health records, said analyst Ray Wang, CEO of Constellation Research.

It will likely continue making acquisitions in support of its health care business, given the market's growth due to the world's aging population and solid margins, Wang said. The strategy also gives Oracle an opportunity to sell its database and ERP (enterprise resource planning) software to health care providers as well, he added.


Follow Us

Join the newsletter!

Error: Please check your email address.

Featured

Slideshows

Sizing up the NZ security spectrum - Where's the channel sweet spot?

Sizing up the NZ security spectrum - Where's the channel sweet spot?

From new extortion schemes, outside threats and rising cyber attacks, the art of securing the enterprise has seldom been so complex or challenging. With distance no longer a viable defence, Kiwi businesses are fighting to stay ahead of the security curve. In total, 28 per cent of local businesses faced a cyber attack last year, with the number in New Zealand set to rise in 2017. Yet amidst the sensationalism, media headlines and ongoing high profile breaches, confusion floods the channel, as partners seek strategic methods to combat rising sophistication from attackers. In sizing up the security spectrum, this Reseller News roundtable - in association with F5 Networks, Kaspersky Lab, Tech Data, Sophos and SonicWall - assessed where the channel sweet spot is within the New Zealand channel. Photos by Maria Stefina.

Sizing up the NZ security spectrum - Where's the channel sweet spot?
Show Comments